MEDICAL INQUIRIES MEDICAL INQUIRIES

THERAPEUTIC AREAS THERAPEUTIC AREAS

DISEASE AWARENESS DISEASE AWARENESS

DRUG PORTFOLIO DRUG PORTFOLIO

CONGRESSES AND PUBLICATIONS CONGRESSES AND PUBLICATIONS

Call 1-888-275-7376
(8-5:30 ET M-F)

Submit Med Info Request

Adverse Event:
1-800-283-8088, ext. 5563

eMedI Chat: Medical Information Database

Please click the eMedI Chat icon in the lower right corner of your screen to use our chatbot and search the Medical Information database

Temperature Stability Calculator

Have a question about a temperature excursion?

Therapeutic Areas

Discover our resource library on diseases, products, congresses, publications, and more, organized by therapeutic areas

Disease Awareness

Find information on disease areas of interest

Marketed Products

Find information on our marketed products

Pipeline Agents

Find information on our pipeline agents

Congress Presentations

Explore our library of congress presentations

Journal Publications

Discover our library of select journal publications

eMedI Chat

Avelumab Journal Publications

Search results containing information about pipeline products (current or former) or investigational uses of products do not imply Food and Drug Administration (FDA) approval for these products or uses, nor does it establish the safety or efficacy of these products or uses. There is no guarantee that the pipeline products or investigational uses will receive FDA approval. EMD Serono, Inc. does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

Avelumab in combination with cetuximab and chemotherapy as first-line treatment for patients with advanced squamous NSCLC

Andric | JTO Clin Res Rep. 2023;4(2):100461.

Avelumab, an Anti-Programmed death-ligand 1 Antibody, in Patients with Refractory Metastatic Urothelial Carcinoma: Results from a Multicenter, Phase Ib Study.

Apolo | J Clin Oncol. 2017;35(19):2117-2124.

Avelumab as Second-Line Therapy for Metastatic, Platinum-Treated Urothelial Carcinoma in the Phase Ib JAVELIN Solid Tumor Study: 2-Year Updated Efficacy and Safety Analysis.

Apolo | J Immunother Cancer. 2020;8(2):e001246.

Avelumab Expanded Access Program in Metastatic Merkel Cell Carcinoma: Efficacy and Safety Findings from Patients in Europe and the Middle East.

Ascierto | Int J Cancer. 2021;149(11):1926-1934.

Axitinib Plus Avelumab in the Treatment of Recurrent Glioblastoma: A Stratified, Open-Label, Single-Center Phase 2 Clinical Trial (GliAvAx).

Awada | J Immunother Cancer. 2020;8(2):e001146.

Phase III, Randomised Trial of Avelumab Versus Physician's Choice of Chemotherapy as Third-Line Treatment of Patients with Advanced Gastric or Gastro-Oesophageal Junction Cancer: Primary Analysis of JAVELIN Gastric 300.

Bang | Ann Oncol. 2018;29(10):2052-2060.

Avelumab Versus Docetaxel in Patients with Platinum-Treated Advanced Non-Small-Cell Lung Cancer (JAVELIN Lung 200): An Open-Label, Randomised, Phase 3 Study.

Barlesi | Lancet Oncol. 2018;19(11):1468-1479.

Incidence of safety events after immune checkpoint inhibitor initiation for advanced-stage non-small-cell lung cancer: a real-world study

Beachler | Future Oncol. 2022;18(26):2891-2901.

Evaluating real-world characteristics of patients with advanced urothelial carcinoma eligible for avelumab maintenance therapy: a multicountry retrospective medical chart review

Bellmunt | Clin Genitourin Cancer. 2023;21(4):459-466.

Real-World Outcomes Among Us Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy.

Bhanegaonkar | Adv Ther. 2021;38(5):2644-2661.

Real-World Clinical Outcomes in Patients with Locally Advanced or Metastatic Merkel Cell Carcinoma Treated in U.S. Oncology Clinical Practices: Results from SPEAR-Merkel.

Bhanegaonkar | Oncologist. 2021;26(9):e1633-e1643.

Health-Related Quality of Life Trajectory of Treatment-Naive Patients with Merkel Cell Carcinoma Receiving Avelumab.

Bharmal | Future Oncol. 2020;16(27):2089-2099.

Successful Rechallenge with Avelumab in Merkel Cell Carcinoma.

Amiot | Eur J Cancer. 2021;153:96-97.

Association of Neutrophil-to-Lymphocyte Ratio with Efficacy of First-Line Avelumab plus Axitinib vs Sunitinib in Patients with Advanced Renal Cell Carcinoma Enrolled in the Phase 3 JAVELIN Renal 101 trial.

Bilen | Clin Cancer Res. 2021:Epub Nov 19.

Association of neutrophil-to-lymphocyte ratio with efficacy of first-line avelumab plus axitinib vs. sunitinib in patients with advanced renal cell carcinoma enrolled in the phase 3 JAVELIN Renal 101 trial

Bilen | Clin Cancer Res. 2022;28(4):738-747.

Clinical and economic outcomes in patients with metastatic urothelial carcinoma receiving first-line systemic treatment (the IMPACT UC I study)

Bilen | Oncologist. 2023;28(9):790-798.

Severe Demyelinating Polyneuropathy and Cranial Neuropathy During Avelumab Treatment of Metastatic Merkel Cell Carcinoma.

Bilic | Clin Neuropharmacol. 2021;44(5):193-195.

Antibody-Dependent Cellular Cytotoxicity Activity of a Novel Anti-PD-L1 Antibody Avelumab (MSB0010718C) on Human Tumor Cells.

Boyerinas | Cancer Immunol Res. 2015;3(10):1148-1157.

Physician reported treatment patterns and outcomes in metastatic bladder cancer in the USA: the CancerMPact((R)) Survey 2020

Bueno | Future Oncol. 2023;20(10):613-622

Hematological Toxicity During Concomitant Treatment with Ruxolitinib and Avelumab for Merkel Cell Carcinoma.

Buonerba | Front Oncol. 2020;10:579914.

Updated Efficacy Results from the JAVELIN Renal 101 Trial: First-Line Avelumab Plus Axitinib Versus Sunitinib in Patients with Advanced Renal Cell Carcinoma.

Choueiri | Ann Oncol. 2020;31(8):1030-1039.

Efficacy and Correlative Analyses of Avelumab Plus Axitinib Versus Sunitinib In Sarcomatoid Renal Cell Carcinoma: Post Hoc Analysis of a Randomized Clinical Trial.

Choueiri | ESMO Open. 2021;6(3):100101.

Preliminary Results for Avelumab Plus Axitinib as First-Line Therapy in Patients with Advanced Clear-Cell Renal-Cell Carcinoma (JAVELIN Renal 100): An Open-Label, Dose-Finding and Dose-Expansion, Phase 1b Trial.

Choueiri | Lancet Oncol. 2018;19(4):451-460.

Exploratory analyses of treatment subgroup interaction by PD-L1 status and according to PD-L1 expression in the JAVELIN Bladder 100 trial

Climent | Clin Transl Oncol. Published online December 15, 2023.

Real-World Clinical Outcomes with First-Line Avelumab in Locally Advanced/Metastatic Merkel Cell Carcinoma in the USA: SPEAR-Merkel.

Cowey | Future Oncol. 2021;17(18):2339-2350.

Early Objective Response to Avelumab Treatment is Associated with Improved Overall Survival in Patients with Metastatic Merkel Cell Carcinoma.

D'Angelo | Cancer Immunol Immunother. 2019;68(4):609-618.

Avelumab in Patients with Previously Treated Metastatic Merkel Cell Carcinoma (JAVELIN Merkel 200): Updated Overall Survival Data After >5 years of Follow-Up.

D'Angelo | ESMO Open. 2021;6(6):100290.

Avelumab in Patients with Previously Treated Metastatic Merkel Cell Carcinoma: Long-Term Data and Biomarker Analyses from the Single-Arm Phase 2 JAVELIN Merkel 200 trial.

D'Angelo | J Immunother Cancer. 2020;8(1):e000674.

First-Line Avelumab in a Cohort of 116 Patients with Metastatic Merkel Cell Carcinoma (JAVELIN Merkel 200): Primary and Biomarker Analyses of a Phase II Study.

D'Angelo | J Immunother Cancer. 2021;9(7):e002646.

Efficacy and Safety of First-Line Avelumab Treatment in Patients with Stage IV Metastatic Merkel Cell Carcinoma: A Preplanned Interim Analysis of a Clinical Trial.

D'Angelo | JAMA Oncol. 2018;4(9):e180077.

Avelumab, an Anti-PD-L1 Antibody, in Patients with Locally Advanced or Metastatic Breast Cancer: A Phase 1b JAVELIN Solid Tumor Study.

Dirix | Breast Cancer Res Treat. 2018;167(3):671-686.

Immuno-Radiotherapy with Cetuximab and Avelumab for Advanced Stage Head and Neck Squamous Cell Carcinoma: Results from a Phase-I Trial.

Elbers | Radiother Oncol. 2020;142:79-84.

Maintenance Avelumab for Metastatic Urothelial Cancer: A New Standard of Care.

Erck | Cancer Biol Ther. 2020;21(12):1095-1096.

Avelumab Phase II Clinical Trial of Axitinib and Avelumab in Patients with Recurrent/Metastatic Adenoid Cystic Carcinoma

Ferrarotto | J Clin Oncol. 2023;41(15):2843-2851.

Case Report: Clinical Experience with Avelumab in Patients with Metastatic Merkel Cell Carcinoma and Brain Metastases Treated in Europe.

Fife | Front Oncol. 2021;11:672021.

A phase II open-label trial of avelumab plus axitinib in previously treated non-small-cell lung cancer or treatment-naive, cisplatin-ineligible urothelial cancer

Galffy | ESMO Open. 2023;8(3):101173.

Avelumab as an Emerging Therapy for Eyelid and Periocular Merkel Cell Carcinoma.

Garcia | Int Ophthalmol Clin. 2020;60(2):91-102.

Activity and Tolerability of Maintenance Avelumab Immunotherapy after First Line Polychemotherapy Including Platinum in Patients with Locally Advanced or Metastatic Squamous Cell Penile Carcinoma: PULSE.

Gassian | Bull Cancer. 2020;107(5S):eS16-eS21.

A Fully Human IgG1 Anti-PD-L1 MAb in An In Vitro Assay Enhances Antigen-Specific T-Cell Responses.

Grenga | Clin Transl Immunology. 2016;5(5):e83.

Impact of prior cytoreductive nephrectomy on efficacy in patients with synchronous metastatic renal cell carcinoma treated with avelumab plus axitinib or sunitinib: Post hoc analysis from the JAVELIN Renal 101 phase 3 trial

Grimm | Eur Urol. 2024;85(1):8-12.

Model-based characterization of the bidirectional interaction between pharmacokinetics and tumor growth dynamics in patients with metastatic Merkel cell carcinoma treated with avelumab

Grisic | Clin Cancer Res. 2022;28(7):1363-1371.

Avelumab First-Line Maintenance in Locally Advanced or Metastatic Urothelial Carcinoma: Applying Clinical Trial Findings to Clinical Practice.

Grivas | Cancer Treat Rev. 2021;97:102187.

Management of patients with advanced urothelial carcinoma in an evolving treatment landscape: A qualitative study of provider perspectives of first-line therapies

Grivas | Clin Genitourin Cancer. 2022;20(2):114-122.

Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice

Grivas | ESMO Open. 2023;8(6):102050.

Patient-reported outcomes from JAVELIN Bladder 100: Avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma

Grivas | Eur Urol. 2023;83(4):320-328.

Avelumab first-line maintenance therapy for advanced urothelial carcinoma: comprehensive clinical subgroup analyses from the JAVELIN Bladder 100 phase 3 trial

Grivas | Eur Urol. 2023;84(1):95-108.

Preferences for first-line treatment of advanced urothelial carcinoma among US practicing oncologists and patients

Grivas | Future Oncol. 2023;19(5):369-383.

Open-Label Randomized Multi-Center Phase 2 Study: Gemcitabine Cisplatin Plus Avelumab or Gemcitabine Cisplatin as First-Line Treatment of Patients with Locally Advanced or Metastatic Urothelial Bladder Carcinoma: GCisAve.

Gross-Goupil | Bull Cancer. 2020;107(5S):eS1-eS7.

Avelumab for Platinum-Ineligible/Refractory Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck: Phase Ib Results from the JAVELIN Solid Tumor Trial.

Guigay | J Immunother Cancer. 2021;9(10):Epub Oct 20.

Evaluating oncologists' practice patterns and decision-making in locally advanced or metastatic urothelial carcinoma: The US physician PARADIGM study

Gupta | Oncologist. 2024;29(3):244-253.

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

Haanen | ESMO Open. 2023;8(3):101210.

Real-world symptoms, disease burden, resource use and quality of life in US patients with advanced renal cell cancer

Hall | Future Oncol. 2021;17(17):2169-2182.

Avelumab in Combination Regimens for Relapsed/Refractory DLBCL: Results from the Phase Ib JAVELIN DLBCL Study.

Hawkes | Target Oncol. 2021;16(6):761-771.

Avelumab for Metastatic or Locally Advanced Previously Treated Solid Tumours (JAVELIN Solid Tumor): A Phase 1a, Multicohort, Dose-Escalation Trial.

Heery | Lancet Oncol. 2017;18(5):587-598.

Avelumab in Relapsed/Refractory Classical Hodgkin Lymphoma: Phase 1b Results from the JAVELIN Hodgkins Trial.

Herrara | Blood Adv. 2021;5(17):3387-3396.

The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma

Hoffman-Censits | Future Oncol. 2023;20(4):179-190.

Long-term avelumab in advanced non-small-cell lung cancer: summaries and post hoc analyses from JAVELIN Solid Tumor

Hrinczenko | Future Oncol. 2022;18(11):1333-1342.

Effects of early vs delayed progression on clinical and economic outcomes in patients with metastatic renal cell carcinoma treated with tyrosine kinase inhibitors as first-line therapy: results from the IMPACT RCC claims data analysis

Hutson | J Manag Care Spec Pharm. 2021;27(9):1171-1181.

Avelumab in Newly Diagnosed glioblastoma.

Jacques | Neurooncol Adv. 2021;3(1):vdab118.

Avelumab Internalization by Human Circulating Immune Cells is Mediated by Both Fc Gamma Receptor and PD-L1 Binding.

Jin | Oncoimmunology. 2021;10(1):1958590.

Avelumab in Combination with Eribulin Mesylate in Metastatic Urothelial Carcinoma: BTCRC GU-051, a Phase 1b Study.

Joshi | Eur Urol Focus. 2022;8(2):483-490.

How assessment-schedule matching limits bias when comparing progression-free survival in single-arm studies: an application in second-line urothelial carcinoma treatments

Kapetanakis | Value Health. 2021;24(8):1137-1144.

Updated Efficacy of Avelumab in Patients with Previously Treated Metastatic Merkel Cell Carcinoma After >/=1 Year of Follow-Up: JAVELIN Merkel 200, A Phase 2 Clinical Trial.

Kaufman | J Immunother Cancer. 2018;6(1):7.

Avelumab in Patients with Chemotherapy-Refractory Metastatic Merkel Cell Carcinoma: A Multicentre, Single-Group, Open-Label, Phase 2 Trial.

Kaufman | Lancet Oncol. 2016;17(10):1374-1385.

Avelumab, a PD-L1 Inhibitor, in Combination with Hypofractionated Radiotherapy and the Abscopal Effect in Relapsed Refractory Multiple Myeloma.

Kazandjian | Oncologist. 2021;26(4):288-e541.

Undertreatment in patients with advanced urothelial cancer: systematic literature review and meta-analysis

Kearney | Future Oncol. 2023;20(16):1123-1137.

Safety Profile of Avelumab in Patients with Advanced Solid Tumors: A Pooled Analysis of Data from the Phase 1 JAVELIN Solid Tumor and Phase 2 JAVELIN Merkel 200 Clinical Trials.

Kelly | Cancer. 2018;124(9):2010-2017.

Efficacy and Immune-Related Adverse Event Associations in Avelumab-Treated Patients.

Kelly | J Immunother Cancer. 2020;8(2):e001427.

Avelumab for the Treatment of Relapsed or Refractory Extranodal NK/T-cell Lymphoma: An Open-Label Phase 2 Study.

Kim | Blood. 2020;136(24):2754-2763.

Modeling challenges in cost-effectiveness analysis of first-line immuno-oncology therapies in non-small cell lung cancer: a systematic literature review

Kongnakorn | Pharmacoeconomics. 2022;40(2):183-201.

Avelumab in Combination with Axitinib as First-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Results from the Phase 1b VEGF Liver 100 Trial.

Kudo | Liver Cancer. 2021;10(3):249-259.

Avelumab Combined with Stereotactic Ablative Body Radiotherapy in Metastatic Castration-Resistant Prostate Cancer: The Phase 2 ICE-PAC Clinical Trial.

Kwan | Eur Urol. 2021:Epub Sep 4.

Patient Experiences with Avelumab in Treatment-Naive Metastatic Merkel Cell Carcinoma: Longitudinal Qualitative Interview Findings from JAVELIN Merkel 200, a Registrational Clinical Trial.

Lambert | Patient. 2020;13(4):457-467.

Survival Analysis in Patients with Metastatic Merkel Cell Carcinoma Treated with Avelumab.

Lanitis | Adv Ther. 2019;36(9):2327-2341.

Avelumab first-line maintenance therapy: managing patients with advanced urothelial carcinoma

Lapuente | Clin J Oncol Nurs. 2023;27(1):71-80.

Avelumab plus axitinib as first-line therapy for advanced renal cell carcinoma: Long-term results from the JAVELIN Renal 100 phase Ib trial

Larkin | Oncologist. 2023;28(4):333-340.

Long-Term Response to Avelumab and Management of Oligoprogression in Merkel Cell Carcinoma: A Case Report.

Leao | World J Clin Cases. 2021;9(18):4829-4836.

Avelumab first-line maintenance plus best supportive care (BSC) vs. BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Asian subgroup analysis

Lee | Urol Oncol. 2023;41(5):256.e17-256.e25.

Phase II Study of Avelumab in Patients with Advanced Hepatocellular Carcinoma Previously Treated with Sorafenib.

Lee DW | Clin Cancer Res. 2020.

Avelumab Plus Standard-of-Care Chemoradiotherapy Versus Chemoradiotherapy Alone in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and Neck: A Randomised, Double-Blind, Placebo-Controlled, Multicentre, Phase 3 Trial.

Lee NY | Lancet Oncol. 2021;22(4):450-462.

Avelumab and Axitinib in the Treatment of Renal Cell Carcinoma: Safety and Efficacy.

Lesli | Expert Rev Anticancer Ther. 2020;20(5):343-354.

Avelumab for Advanced Merkel Cell Carcinoma in the Netherlands: A Real-World Cohort.

Levy | J Immunother Cancer. 2020;8(2):e001076.

Avelumab in paediatric patients with refractory or relapsed solid tumours: dose-escalation results from an open-label, single-arm, phase 1/2 trial

Loeb | Cancer Immunol Immunother. 2022;71(10):2485-2495.

Randomized phase II trial of avelumab alone or in combination with cetuximab for patients with previously treated, locally advanced, or metastatic squamous cell anal carcinoma: the CARACAS study

Lonardi | J Immunother Cancer. 2021;9(11):e002996.

A Cost-Effectiveness Analysis: First-Line Avelumab plus Axitinib Versus Sunitinib for Advanced Renal-Cell carcinoma.

Lu | Front Pharmacol. 2020;11:619.

Comparison of tumor assessments using RECIST 1.1 and irRECIST, and association with overall survival

Manitz | J Immunother Cancer. 2022;10(2):e003302.

Avelumab as first-line maintenance treatment in locally advanced or metastatic urothelial carcinoma

Mansinho | Adv Ther. 2023;40(10):4134-4150.

Cetuximab Rechallenge Plus Avelumab in Pretreated Patients with RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial.

Martinelli | JAMA Oncol. 2021;7(10):1529-1535.

Avelumab As Neoadjuvant Therapy in Patients with Urothelial Non-Metastatic Muscle Invasive Bladder Cancer: A Multicenter, Randomized, Non-Comparative, Phase II Study (Oncodistinct 004 – AURA Trial).

Martinez Chanza | BMC Cancer. 2021;21(1):1292.

Model-informed drug development supporting the approval of the avelumab flat-dose regimen in patients with advanced renal cell carcinoma

Masters | CPT Pharmacometrics Syst Pharmacol. 2022;11(4):458-468.

A Case Report of Leptomeningeal Carcinomatosis Secondary to Recurrent Merkel Cell Carcinoma After Avelumab.

Mendoza | Perm J. 2021;25:20.235.

Phase III trial of Avelumab Maintenance After First-Line Induction Chemotherapy Versus Continuation of Chemotherapy in Patients with Gastric Cancers: Results from JAVELIN Gastric 100.

Moehler | J Clin Oncol. 2021;39(9):966-977.

Chemotherapy with or without Avelumab Followed by Avelumab Maintenance Versus Chemotherapy Alone in Patients with Previously Untreated Epithelial Ovarian Cancer (JAVELIN Ovarian 100): An Open-Label, Randomised, Phase 3 Trial.

Monk | Lancet Oncol. 2021;22(9):1275-1289.

Avelumab Plus Axitinib Versus Sunitinib for Advanced Renal-Cell Carcinoma.

Motzer | N Engl J Med. 2019;380(12):1103-1115.

Avelumab Plus Axitinib Versus Sunitinib in Advanced Renal Cell Carcinoma: Biomarker Analysis of the Phase 3 JAVELIN Renal 101 Trial.

Motzer | Nat Med. 2020;26(11):1733-1741.

Treatment patterns and clinical outcomes in patients with advanced non-small cell lung cancer initiating first-line treatment in the US community oncology setting: a real-world retrospective observational study

Nadler | J Cancer Res Clin Oncol. 2021;147(3):671-690.

Changing Body Weight-Based Dosing to a Flat Dose for Avelumab in Metastatic Merkel Cell and Advanced Urothelial Carcinoma.

Novakovic | Clin Pharmacol Ther. 2020;107(3):588-596.

Avelumab Versus Docetaxel in Patients with Platinum-Treated Advanced NSCLC: 2-Year Follow-Up from the JAVELIN Lung 200 Phase 3 trial.

Park | J Thorac Oncol. 2021;16(8):1369-1378.

Impact of Subsequent Immune Checkpoint Inhibitor Treatment on Overall Survival with Avelumab vs Docetaxel in Platinum-Treated Advanced NSCLC: Post Hoc Analyses from the Phase 3 JAVELIN Lung 200 Trial.

Park | Lung Cancer. 2021;154:92-98.

The role of nurses in the management of adverse events in patients receiving first-line axitinib plus immuno-oncology agents for advanced renal cell carcinoma

Parreira | Semin Oncol Nurs. 2024;40(1):151545.

Avelumab in Metastatic Urothelial Carcinoma after Platinum Failure (JAVELIN Solid Tumor): Pooled Results from Two Expansion Cohorts of An Open-Label, Phase 1 Trial.

Patel |Lancet Oncol. 2018;19(1):51-64.

Cost-Effectiveness of Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma in the United States.

Peng | Adv Ther. 2021;38(12):5710-5720.

Plain language summary of results from the JAVELIN Bladder 100 study: avelumab maintenance treatment for advanced urothelial cancer

Powels | Future Oncology 2022 18:19, 2361-2371.

Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after ≥2 years of follow-up

Powles | JCO 2023;41:3486-3492.

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma.

Powles | N Engl J Med. 2020;383(13):1218-1230.

Avelumab maintenance in advanced urothelial carcinoma: biomarker analysis of the phase 3 JAVELIN Bladder 100 trial

Powles | Nat Med. 2021;27(12):2200-2211.

Avelumab Alone or in Combination with Chemotherapy Versus Chemotherapy Alone in Platinum-Resistant or Platinum-Refractory Ovarian Cancer (JAVELIN Ovarian 200): An Open-Label, Three-Arm, Randomised, Phase 3 Study.

Pujade-Lauraine | Lancet Oncol. 2021;22(7):1034-1046.

Avelumab versus platinum-based doublet chemotherapy as first-line treatment for patients with high-expression programmed death-ligand 1-positive metastatic NSCLC: primary analysis from the phase 3 JAVELIN Lung 100 trial

Reck | J Thorac Oncol. 2024;19(2):297-313.

Perceived unmet needs in patients living with advanced bladder cancer and their caregivers: Infodemiology study using data from social media in the United States

Renner | JMIR Cancer. 2022;8(3):e37518.

Prospective cardiovascular surveillance of immune checkpoint inhibitor-based combination therapy in patients with advanced renal cell cancer: data from the phase III JAVELIN Renal 101 trial

Rini | J Clin Oncol. 2022 Jun 10;40(17):1929-1938.

Avelumab or talazoparib in combination with binimetinib in metastatic pancreatic ductal adenocarcinoma: dose-finding results from phase Ib of the JAVELIN PARP MEKi trial

Rodon Ahnert | ESMO Open. 2023;8(4):101584.

A Phase 1b/2 Study of Azacitidine with PD-L1 Antibody Avelumab in Relapsed/Refractory Acute Myeloid Leukemia.

Saxena | Cancer. 2021;127(20):3761-3771.

Avelumab plus talazoparib in patients with BRCA1/2- or ATM-altered advanced solid tumors: results from JAVELIN BRCA/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial

Schram | JAMA Oncol. 2023;9(1):29-39.

A Phase Ib/II Study of Pepinemab in Combination with Avelumab in Advanced Non-Small Cell Lung Cancer.

Shafique | Clin Cancer Res. 2021;27(13):3630-3640.

Efficacy and Safety-In Analysis of Short-Course Radiation Followed by mFOLFOX-6 Plus Avelumab for Locally Advanced Rectal Adenocarcinoma.

Shamseddine | Radiat Oncol. 2020;15(1):233.

Avelumab Plus Axitinib Therapy for Renal Cell Carcinoma in a Patient with Pulmonary Alveolar Proteinosis: A Case Report.

Shimizu | Urol Case Rep. 2021;39:101843.

Case-control matching-guided exposure-efficacy relationship for avelumab in patients with urothelial carcinoma

Soltantabar | CPT Pharmacometrics Syst Pharmacol. 2023;12(12):2001-2012.

Immune-related adverse events with PD-1 versus PD-L1 inhibitors: a meta-analysis of 8730 patients from clinical trials

Sonpavde | Future Oncol. 2021;17(19):2545-2558.

Avelumab first-line maintenance for advanced urothelial carcinoma: analysis from JAVELIN Bladder 100 by duration of first-line chemotherapy and interval before maintenance

Sridhar | Eur Urol. 2024;85(2):154-163.

First-in-human phase Ib trial of M9241 (NHS-IL12) plus avelumab in patients with advanced solid tumors, including dose expansion in patients with advanced urothelial carcinoma

Strauss | J Immunother Cancer. 2023;11(5):e005813.

A Case of Clear Cell Renal Cell Carcinoma with Vena Cava Thrombus Responding to Presurgical Avelumab, and Axitinib.

Suzuki | IJU Case Rep. 2021;4(6):412-416.

Avelumab Versus Standard Second Line Treatment Chemotherapy in Metastatic Colorectal Cancer Patients with Microsatellite Instability: The SAMCO-PRODIGE 54 Randomised Phase II Trial.

Taieb | Dig Liver Dis. 2021;53(3):318-323.

Avelumab-Cetuximab-Radiotherapy Versus Standards of Care in Locally Advanced Squamous-Cell Carcinoma of the Head and Neck: The Safety Phase of a Randomised Phase III Trial GORTEC 2017-01 (REACH).

Tao | Eur J Cancer. 2020;141:21-29.

Pharmacometric modeling and machine learning analyses of prognostic and predictive factors in the JAVELIN Gastric 100 phase III trial of avelumab

Terranova | CPT Pharmacometrics Syst Pharmacol. 2022;11(3):333-347.

Efficacy and safety of avelumab plus axitinib in elderly patients with advanced renal cell carcinoma: extended follow-up results from JAVELIN Renal 101

Tomita | ESMO Open. 2022;7(2):100450.

Association of C-reactive protein with efficacy of avelumab plus axitinib in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

Tomita | ESMO Open. 2022;7(5):100564.

Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101

Tomita | ESMO Open. 2023;8(6):102034.

Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis

Tomita | Int J Clin Oncol. 2022;27(2):383-395.

Avelumab Monotherapy as First-Line or Second-Line Treatment in Patients with Metastatic Renal Cell Carcinoma: Phase Ib Results from the JAVELIN Solid Tumor Trial.

Vaishampayan | J Immunother Cancer. 2019;7(1):275.

Application of statistical machine learning in biomarker selection

Vashistha | Sci Rep. 2023;13(1):18331.

Efficacy and Safety of First-Line Avelumab in Patients with Advanced Non-Small Cell Lung Cancer: Results from a Phase Ib Cohort of the JAVELIN Solid Tumor Study.

Verschraegen | J Immunother Cancer. 2020;8(2):e001064.

Avelumab dose selection for clinical studies in pediatric patients with solid tumors

Vugmeyster | Clin Pharmacokinet. 2022;61(7):985-995.

Efficacy and Safety of Avelumab Treatment in Patients with Metastatic Merkel Cell Carcinoma: Experience from a Global Expanded Access Program.

Walker | J Immunother Cancer. 2020;8(1):e000313.

Avelumab first-line maintenance treatment in advanced bladder cancer: practical implementation steps for infusion nurses

Wood | J Infus Nurs. 2022;45(3):142-153.

Avelumab plus talazoparib in patients with advanced solid tumors: The JAVELIN PARP Medley nonrandomized controlled trial

Yap |JAMA Oncol. 2023;9(1):40-50.

Impact of therapy management on axitinib-related adverse events in patients with advanced renal cell carcinoma receiving first-line axitinib + checkpoint inhibitor

Zakharia | Clin Genitourin Cancer. 2023;21(5):e343-e351.

Real-world treatment patterns and outcomes in PD-L1-positive non-small cell lung cancer

Zhang | Immunotherapy. 2021;13(18):1521-1533.

Health care resource utilization and costs associated with advanced or metastatic nonsmall cell lung cancer in the United States

Zhang | J Manag Care Spec Pharm. 2022;28(2):255-265.

Avelumab Plus Axitinib vs. Sunitinib for Advanced Renal-Cell Carcinoma.

Zhang | Transl Cancer Res. 2019;8(Suppl 6):S585-S588.

A Phase I Clinical Trial of Avelumab in Combination with Decitabine as First Line Treatment of Unfit Patients with Acute Myeloid Leukemia.

Zheng | Am J Hematol. 2021;96(2):E46-E50.

Clinical outcomes, costs, and healthcare resource utilization in patients with metastatic Merkel cell carcinoma treated with immune checkpoint inhibitors vs chemotherapy

Zheng | Clinicoecon Outcomes Res. 2021;13:213-226.

Real-world clinical and economic outcomes in selected immune-related adverse events among patients with cancer receiving immune checkpoint inhibitors

Zheng | Oncologist. 2021;26(11):e2002-e2012.

This site is intended for US healthcare professionals only.

DISCLAIMER: This site contains medical information that is intended for healthcare providers of the United States only. The medical information contained on this site is not meant to substitute for the advice provided by a medical professional. Canadian residents should consult the EMD Serono Canada Inc. website at www.emdserono.ca for information on products and services approved in Canada. Use and access of this site is subject to the terms and conditions as set out in our Legal Statement and Privacy Policy.

EMD Serono is the Healthcare business of Merck KGaA, Darmstadt, Germany, in the United States and Canada.

US-MULNP-00023 09/24

By clicking this link, you are leaving medical.emdserono.com. Please, note that this link will take you to a website on which different Privacy Policy and Conditions may apply. EMD Serono accepts no responsibility for websites not controlled directly by us. Please check Privacy Policy and Conditions of the linked website.

Welcome to EMD Serono Medical Information!

Help us direct you to the right information by selecting one of the following options:

Avelumab Journal Publications

Cookie Disclaimer

Welcome to EMD Serono Medical Information!